Harmony Biosciences Holdings, I — Earnings Quality Grade A
HRMY · Healthcare
Strong financial health
Screening Summary
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 41 days, change -2 days YoY
AR growth 16.6% vs revenue growth 21.5%
Revenue 21.5%, CFFO 58.4%. Cash follows revenue
Expense Quality
Inventory -25.6% vs COGS 26.5%. Normal
CapEx growth -73.1% vs revenue 21.5%. Normal
SG&A/Gross Profit = 40.6%. Normal
Gross margin 77.2%, change -0.9pp. Stable
Cash Flow Quality
CFFO/NI = 2.19. Profits backed by cash
FCF $0.3B, FCF/NI = 2.19
Accruals ratio = -14.9%. Low accruals
Cash $0.8B covers debt $0.2B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = 0.6x. Healthy
Other assets grew 147.8% vs revenue 21.5%
No write-off data
Acquisition Risk
FCF after acquisitions positive
No goodwill
Manipulation Score
Insufficient data
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25